Literature DB >> 7127320

Augmentation of the human immune response by cyclophosphamide.

D Berd, M J Mastrangelo, P F Engstrom, A Paul, H Maguire.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7127320

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  21 in total

1.  Renal cell carcinoma treated by vaccines for active specific immunotherapy: correlation of survival with skin testing by autologous tumor cells.

Authors:  C S McCune; R W O'Donnell; D M Marquis; D M Sahasrabudhe
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

2.  Cell-mediated immunity is enhanced by cytostatic drugs continuously released at the site of antigenic stimulation.

Authors:  A M Claessen; H Valster; H Bril; S Meyer; R J Scheper
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer.

Authors:  David Miles; Henri Roché; Miguel Martin; Timothy J Perren; David A Cameron; John Glaspy; David Dodwell; Joanne Parker; José Mayordomo; Alejandro Tres; James Lee Murray; Nuhad K Ibrahim
Journal:  Oncologist       Date:  2011-05-14

4.  Advanced colon cancer: antiprogressive immunotherapy using an autologous hemoderivative.

Authors:  Eduardo Lasalvia-Prisco; Emilio Garcia-Giralt; Silvia Cucchi; Jesús Vázquez; Eduardo Lasalvia-Galante; Wilson Golomar; Joshemaria Larrañga
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

5.  Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen.

Authors:  Neil L Berinstein; Gregory T Wolf; Paul H Naylor; Lorraine Baltzer; James E Egan; Harvey J Brandwein; Theresa L Whiteside; Lynn C Goldstein; Adel El-Naggar; Cecile Badoual; Wolf-Herve Fridman; J Michael White; John W Hadden
Journal:  Cancer Immunol Immunother       Date:  2011-11-06       Impact factor: 6.968

6.  Cancer chemotherapeutics as immunomodulators.

Authors:  F Spreafico; A Vecchi; F Colotta; A Montovani
Journal:  Springer Semin Immunopathol       Date:  1985

7.  Evaluation of lymphocyte immunity in breast cancer patients.

Authors:  J F Head; R L Elliott; J L McCoy
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

8.  Importance in timing of cyclophosphamide on the enhancement of interleukin-2-induced cytolysis.

Authors:  E Katsanis; M A Bausero; A C Ochoa; C M Loeffler; B R Blazar; A S Leonard; P M Anderson
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

9.  Augmentation of host antitumor immunity by low doses of cyclophosphamide and mafosfamide in two animal tumor models.

Authors:  T Reissmann; R Voegeli; J Pohl; P Hilgard
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

10.  Randomized phase II clinical trial of chemo-immunotherapy in advanced nonsmall cell lung cancer.

Authors:  Eduardo Lasalvia-Prisco; Emilio Garcia-Giralt; Jesús Vázquez; Marta Aghazarian; Eduardo Lasalvia-Galante; Joshemaria Larrañaga; Gonzalo Spera
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.